Clinical Trial Update: Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

The document reports on Phase 1/Phase 2 results for triweekly cetuximab plus capecitabine as first-line maintenance therapy in KRAS/BRAF wild-type metastatic co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Cetuximab (cetuximab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED